



**PHAARMASIA**

*Phaarmasia Ltd.*

16, Phase III, IDA, Jeedimetla, Hyderabad - 500 055. INDIA.

Tel : 91-40-23095002 / 23095690, Fax : 91-40-23097323

E-mail : phaarmasia@gmail.com, www.phaarmasia.in

CIN : L24239TG1981PLC002915

Date: September 15, 2020

To  
Listing Compliance Department,  
BSE Limited  
P.J Towers, Dalal Street,  
Mumbai-400001

Dear Sir/Madam,

**Sub.:** Sub: Outcome of the Board Meeting held on 15th September, 2020 at 03.30 PM.

Ref Company Scrip Code: 523620

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, this is to inform you, that the Meeting of the Board of Directors of the Company was held earlier today at 29/33, Ancillary Industrial Plots, Govandi, Mumbai – 400043, at 03.30 P.M which concluded at 04.25 P.M. The Board of Directors at this Board meeting transacted and approved the following important agenda's along with other matters:

1. Approved the Un-audited financial results, as approved by the audit committee and reviewed by the statutory auditors for the quarter ended on 30th June, 2020 along with the Limited Review Report issued by the statutory auditor.

Kindly take the above information on records.

Thanking You,

Yours Faithfully,

**For Phaarmasia Limited**

**Urvashi Bhatia**  
**Company Secretary & Compliance Officer**



# SATHULURI & CO. CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To


The Board of Directors of  
PHAARMASIA LIMITED

We have reviewed the accompanying statement of unaudited financial results of **PHAARMASIA LIMITED** ('The Company') for the quarter ended 30<sup>th</sup> June, 2020. This statement is the responsibility of the company's management and has been approved by the board of directors, Our responsibility is to issue a report on these financial statements based on our review

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from **material** misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide **less** assurance than an **audit**. We **have** not performed an audit and accordingly **we** do not express an audit opinion,

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying **statement**, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

For Sathuluri & Co  
Chartered Accountants  
Firm Reg No.006383S



(S.S.Prakash)

Partner

Membership No.292718

UDIN :- 20202710AAAAAS6980 .

Place: Hyderabad

Date: 15/09/2020



(Rs.in Lakhs)

S No	Particulars	Quarter Ended		Year ended	
		June-30,2020	Mar.31, 2020	June-30,2019	Mar.31, 2020
		Un-Audited	Audited	Un-Audited	Audited
<b>1</b>	<b>Income</b>				
	a) Revenue from Operations	525.13	548.57	825.22	2,445.36
	<b>Total Revenue</b> from operations	525.13	548.57	825.22	2,445.36
	b) Other Income	7.04	16.32	13.91	57.77
	<b>Total Income</b>	532.18	564.89	839.13	2,503.14
<b>2</b>	<b>Expenses</b>				
	a) Cost of materials Consumed	223.36	462.53	536.30	1,834.81
	b) Purchases of Stock in Trade				
	c) Changes in inventories	169.99	(110.38)	131.06	(55.36)
	d) Employee benefits expense	30.21	37.82	43.83	158.19
	e) Finance costs	0.20	2.18	0.59	3.68
	f) Depreciation and amortization expense	8.48	9.92	9.57	39.89
	g) Other expenses	92.56	90.67	107.32	425.85
	<b>Total Expenses</b> (a to g)	524.81	492.73	828.67	2,407.07
<b>3</b>	<b>Profit before tax (1-2)</b>	7.36	72.16	10.46	96.07
<b>4</b>	<b>Tax expenses</b>				
	- Income Tax	2.30	19.59	3.19	26.57
	- Deferred Tax	(0.43)	1.10	18.68	15.52
<b>5</b>	<b>Net Profit for the period (3-4)</b>	5.50	51.47	(11.41)	53.98
<b>6</b>	<b>Other comprehensive income</b>				
	a) (i) Items that will not be reclassified to profit or loss		6.74		6.74
	(ii) Income tax relating to items that will not be reclassified to profit or loss		(1.51)		(1.51)
	b) (i) Items that will be reclassified to profit or loss				
	(ii) Income tax relating to items that will be reclassified to profit or loss				
	<b>Total other comprehensive income</b>		5.22		5.22
<b>7</b>	<b>Total Comprehensive income (5+6)</b>	5.50	56.70	(11.41)	59.20
<b>8</b>	<b>Paid-up Equity Share Capital</b> (Rs.10/- per Equity Share)	682.70	682.70	682.70	682.70
<b>9</b>	<b>Other Equity</b>				1,340.85
<b>10</b>	<b>Earnings per share</b> (Face Value of Rs.10/- each)				
	(a) Basic (In Rs.)	0.08	0.75	(0.17)	0.79
	(b) Diluted (In Rs.)	0.08	0.75	(0.17)	0.79

1. The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.

2. The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 15th day of September, 2020

3. The Financial results are reviewed by the Statutory Auditors of the Company as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

4. Estimation uncertainty relating to the global health pandemic on COVID-19

The management has considered the possible effects, if any, that may result from the pandemic relating to COVID - 19 on the carrying amounts of trade receivables & inventories. In assessing the recoverability of receivables, the Company has considered internal and external information upto the date of approval of these financial results including credit reports and economic forecasts. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes and future economic conditions.

5. The entire operations of the Company relate to only one segment. Hence segmental reporting as per Ind AS 108 is not made.

6. Previous Year/ Period figures have been regrouped and recast, wherever necessary, in line with the current period presentation.



By and on behalf of the Board  
for Pharmasia Limited

V.N. Bhaskar Rao  
Whole Time Director  
DIN: 00019052

Place : Hyderabad  
Date : 15-09-2020